Results 31 to 40 of about 3,283 (198)

Comprehensive assessment of the impact of intravitreal faricimab on retinal diseases: A systematic review, meta-analysis, and trial sequential analysis

Pharmacological Research
Background: Faricimab stands as the inaugural and sole bispecific antibody approved by the US Food and Drug Administration (FDA) for intravitreal injection. Nonetheless, the efficacy and safety of intravitreal faricimab remained uncertain.
Guanran Zhang, Xin Wen, Yanrong Li, Junran Sun, Huixun Jia, Xiaodong Sun   +5 more
doaj   +1 more source

1-Year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration

Eye
Faricimab, a bispecific antibody targeting VEGF-A and angiopoietin-2, has shown promise in treating neovascular age-related macular degeneration (nAMD). This study evaluates 1-year outcomes of faricimab in treatment-experienced nAMD patients. This single-
I. Janmohamed, A. Mushtaq, J. Kabbani, Simeon Harrow, Aaruran Nadarajasundaram, A. Ata, H. Monye, Zakariya A Jarrar, S. Hannan, L. Membrey   +9 more
semanticscholar   +1 more source

Efficacy, Durability, and Safety of Faricimab for Diabetic Macular Edema: 1-Year Results from the China RHINE Subpopulation

Ophthalmology and Therapy
Introduction To assess the efficacy, durability, and safety of faricimab compared with aflibercept over 1 year in patients with diabetic macular edema (DME) from the China RHINE subpopulation.
Xiaorong Li, Xiaoling Liu, Qin Jiang, Zhifeng Wu, Mei Han, Qiuyu Chen, Oluwatobi O. Idowu, Ruyuan Liu, Wenxin Liu, Jeffrey R. Willis, Xiaodong Sun   +10 more
doaj   +1 more source

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

Acta Ophthalmologica, EarlyView.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car, Isabelle Huys, Steven Simoens, Arnold G. Vulto   +3 more
wiley   +1 more source

Supplementary Material for: Old Problem in a New Guise: Retinal Pigment Epithelium Tear after Intravitreal Faricimab (Vabysmo^®) Injection

, 2023
This case report describes a 78-year-old patient who developed a tear of the retinal pigment epithelium (RPE) during faricimab (Vabysmo®) therapy. After three consecutive intravitreal aflibercept (Eylea®) injections with persistent disease activity ...
Caroline H. Chilton (412724), Albin M. Ahmed (739857), Elisabeth Schinner (739856), Long Miao (388082)   +3 more
core   +1 more source

Evaluating the Real-World Efficacy and Safety of Intravitreal Faricimab in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review

IJRETINA (International Journal of Retina)
Introduction: Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible vision loss in the elderly. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapies have revolutionized the treatment of nAMD ...
Dany Petra Pranata Barus, Gitalisa Andayani Adriono   +1 more
doaj   +1 more source

Clinical Evaluation of Faricimab in Real-World Diabetic Macular Edema in India- A Multicenter Observational Study

Clinical Ophthalmology
Purpose To evaluate the efficacy of faricimab in real-world clinical settings in India for treating diabetic macular edema (DME) in treatment-naïve and recalcitrant eyes.
Debdulal Chakraborty, Sudipta Das, Aniruddha Maiti, T. Sinha, A. Das, J. Sheth, S. Boral, S. Mondal, K. Nandi   +8 more
semanticscholar   +1 more source

Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration (RISE‐AMD): Safety data

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate real‐world safety experience with aflibercept 8 mg in a large case series of patients with neovascular age‐related macular degeneration (nAMD). Methods Due to a high proportion of patients on short treatment intervals, patients with nAMD at a Danish tertiary retina clinic were systematically switched to aflibercept 8 mg ...
Mary Graciya Karunainathan, Celine Lee, Kaweh Daniel Zohalinejad, Mads Odgaard Mæng, Nanna Würtz Fabrin, Sigurrós Jónsdóttir, Anne Kjærsgaard Hassing, Søren Kveiborg Yde, Charles C. Wykoff, Henrik Vorum, Yousif Subhi, Marie Ørskov, Lasse Jørgensen Cehofski   +12 more
wiley   +1 more source

Real‐world incidence and clinical characteristics of intraocular inflammation following intravitreal faricimab therapy: A safety study

Acta Ophthalmologica, EarlyView.
Abstract Purpose To estimate the real‐world incidence of intraocular inflammation (IOI) following intravitreal faricimab injections at a large, highly specialized tertiary centre. Methods Single‐centre, retrospective cohort study with chart review using an electronic injection database and electronic medical records from November 2023 to August 2024 ...
Miklos Schneider, Leyla Turan, Farah Arif, Jakob Bjerager, Oliver Niels Klefter, Carsten Faber, Yousif Subhi, Javad Nouri Hajari   +7 more
wiley   +1 more source

Switching to faricimab from aflibercept during maintenance treatment period for age-related macular degeneration

Scientific Reports
To compare the short-term treatment outcomes of aflibercept and faricimab for neovascular age-related macular degeneration (nAMD) during the maintenance treatment period, we included 82 eyes of 74 patients who switched from aflibercept to faricimab ...
Misa Masaoka, Kenji Yamashiro
doaj   +1 more source